When the Cure Triggers the Crisis: Rapid-Onset, Life-Threatening Diabetic Ketoacidosis (DKA) as a Consequence of Immune Checkpoint Inhibition with Nivolumab (KIDNEY WEEK 2026) - Oct 2, 2026 - Abstract #SA-PO1282; Pres time: Oct 24, 2026; 10:00 AM - 12:00 PM; Location: Exhibit Hall A, Convention Center; "Clinically, this has a direct implication: Nivoloumab-induced DKA can be life-threatening. The absence of autoantibodies has not been reported before with Nivolumab and does not exclude ICI-induced T1DM, and the pace of deterioration in this case — from a normal A1c to fulminant DKA within months —reinforces the need for close monitoring of immune-mediated adverse events (irAEs)."
Checkpoint inhibition • IO biomarker • Cardiovascular • Diabetes • Endocrine Disorders • Heart Failure • Metabolic Disorders • Nephrology • Oncology • Solid Tumor • Type 1 Diabetes Mellitus • Urothelial Cancer
|
|
Razi Haider Hashmi; Daniel L. Landry; Gregory Lee Braden
|